New blood test assists oncologists with tumour treatment optimization

Thursday, January 5, 2017

Washington: CellMax Life, a precision cancer blood-testing company, on Wednesday announced the availability of CellMax-LBx Liquid Biopsy in India.

CellMax-LBx Liquid BiopsyCellMax-LBx is a cancer blood test that analyses circulating tumour DNA (ctDNA). The assay provides oncologists with a valuable tool in managing their patients’ cancer treatments, monitoring treatment response, and assessing the risk of recurrence, according to a statement.

CellMax-LBx is intended as a supplement to a tissue biopsy, and as an alternative when tissue biopsy is not possible. The test profiles 73 genes from circulating tumour DNA (ctDNA) to identify and assess actionable genomic alterations using CellMax Life’s single-molecule-sequencing SMSEQ platform.

Circulating tumour DNAs (ctDNAs) are small DNA fragments shed by the tumour. Tumour genes may mutate over time, either as the cancer grows, or the treatment suppresses the cancer. ctDNA gives an accurate, real-time picture of these cancer mutations, the statement said.

“The incidence of cancer is expected to increase by 70% over the next two decades. CellMax Life’s goal is to reduce cancer mortality by empowering patients and their doctors to make the most informed health decisions possible, with the necessary frequency,” said Rui Mei, chief scientific officer, CellMax Life.

Categories: Diagnostics, NEWS

Tags: , , , , ,

  More from Diagnostics

New AI able to identify & predict development of cancer symptom clusters

Next generation optical biometry devices market may grow to $450 million by 2028

Biosense Technologies raises $1 million in funding

Nuclear medicine can help avoid unnecessary angioplasty

Faulty gene identified as cause of obesity in world’s heaviest woman

Dr Lal PathLabs to open central labs in Kolkata, Lucknow

Comments »

No comments yet.

Name (required)
E-mail (required - never shown publicly)
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> in your comment.